# CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant

> **NCT03922035** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 36 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **OTHER:** Best Practice
- **DRUG:** Clostridium butyricum CBM 588 Probiotic Strain

## Key facts

- **NCT ID:** NCT03922035
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-18
- **Primary completion:** 2027-02-05
- **Final completion:** 2027-02-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922035, "CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03922035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*